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Abstract
Background—Although obesity is associated with risk for chronic kidney disease (CKD) and 
improved survival, less is known about the associations of obesity with risk of acute kidney injury 
(AKI) and post-AKI mortality.
Methods—In a single-center inception cohort of almost 15,000 critically ill patients, we 
evaluated the association of obesity with AKI and AKI severity, as well as in-hospital and one-
year survival. AKI was defined using the Kidney Disease Outcome Quality Initiative criteria.
Results—The AKI incidence rates for normal, overweight, Class I, II, and III Obesity were 18.6, 
20.6, 22.5, 24.3 and 24.0 percent respectively, and the adjusted odds ratios of AKI were 1.18 [95% 
CI 1.06–1.31], 1.35 [1.19–1.53], 1.47 [1.25–1.73], 1.59 [1.31–1.87], compared to normal weight, 
respectively. Each 5 kg/m2 increase in body mass index (BMI) was associated with a 10% risk 
[95% CI 1.06–1.24; p<0.001] of more severe AKI. Within-hospital and one-year survival rates 
associated with the AKI episodes were similar across BMI categories. In conclusion, obesity is a 
risk factor for AKI injury, which is associated with increased short- and long-term mortality.
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Introduction
As obesity grows as an epidemic, knowledge of its pathophysiologic complications is 
important. Many of the hallmark systemic abnormalities of obesity, including insulin 
resistance, hypertension, and cardiovascular disease, are known contributors to renal 
disease, and more recently, renal-specific pathways, including increased autophagy and 
fibrosis, have been described (1). In addition, the emerging importance of renal vein 
congestion as a determinant of renal function (2) raises questions whether the hemodynamic 
complications of obesity, including obesity hypoventilation, pulmonary hypertension and 
cor pulmonale, may contribute to renal dysfunction.
Although obesity has been associated with chronic kidney disease (CKD) (3–6), it is not 
widely accepted as a risk factor for acute kidney injury (AKI) (7, 8). The incidence of AKI 
in obesity has been described in bariatric surgery (9, 10), cardiac surgery (11–14), and in the 
acute respiratory distress syndrome (15), and a more recent study focused on severe AKI 
requiring dialysis (16). However, to our knowledge, the association of BMI with AKI and 
AKI severity has not been well described in a large representative critically ill population. In 
addition, no study has described the long term outcomes of AKI in critically ill obese 
patients. In CKD, obesity is paradoxically associated with an improved prognosis (17, 18). 
Thus, whereas an episode of AKI is typically associated with worse survival (19, 20), 
whether this association is also true for critically ill obese patients is unknown.
To address the simultaneous associations of obesity with incidence and prognosis of AKI, 
we evaluated a large cohort of patients hospitalized in the intensive-care units (ICU) of a 
single large medical center.
Methods
Study Population
We used the MIMIC-III (Multiparameter Intelligent Monitoring in Intensive Care) database, 
a joint venture managed by the Laboratory for Computational Physiology at Massachusetts 
Institute of Technology (MIT) and the Department of Medicine at the Beth Israel Deaconess 
Medical Center (BIDMC) (21). MIMIC-III contains data from 37,305 unique adult critical 
care admissions between 2001 and 2012 at BIDMC, a 700-bed urban academic medical 
center with 77 adult ICU beds. The database contains high-temporal-resolution data from 
clinical systems, including lab results, electronic documentation, and bedside monitor trends 
and waveforms. Use of the MIMIC II database has been approved by the Institutional 
Review Boards of BIDMC and MIT.
A total of 22,073 individuals had a documented height within the BIDMC electronic 
medical record. Of these, 18,938 had a documented weight upon ICU admission, allowing 
calculation of body mass index (BMI). After exclusion of 743 ESRD patients, 17,140 had 
documentation of renal function. To identify comorbidities and medication exposure, we 
included the 15,470 patients with an admission history and physical examination with 
admission medication lists. Of these, 484 were missing documentation of admission ICU 
vitals, leaving a primary complete case analysis of 14,986.
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Outcomes
The primary outcome was acute kidney injury during ICU admission, as defined by either a 
≥0.3 mg/dL increase within 48 hours or a ≥50 percent increase within 7 days of ICU 
admission, or acute dialysis, in keeping with the Kidney Disease Outcome Quality Initiative 
(KDOQI) guidelines (22). We also explored the association of BMI with severity of AKI. 
Stage I AKI was defined as 50 to 100% increase in admission serum creatinine within 7 
days, Stage II as greater than 100% to 200% increase, and Stage III as greater than 200% 
increase, or the initiation of acute dialysis. Following best practice guidelines, we used the 
admission creatinine to define “baseline”. (23)
To evaluate risk of death during hospitalization and within one year from hospital discharge, 
we linked medical records to the Social Security Death Index.
Exposure
BMI was the primary exposure, categorized in standard World Health Organization 
groupings: <18.5 (underweight), ≥18.5 to <25 (normal), ≥25 to <30 (overweight), ≥30 to 
<35 (Class I obesity), ≥35 to <40 (Class II obesity), and BMI≥40 (Class III obesity), and as 
a continuous variable per 5 units of BMI.
Because weight at the time of critical illness might not reflect usual body weight, we 
performed a validation study among 150 randomly selected subjects within the dataset to 
determine body weights measurements obtained during noncritical illness. A total of 86 
individuals had documented weights during noncritical illness in the electronic medical 
record. The Spearman correlation coefficient between ICU and non-ICU body weights 
measurements was 0.93 (p<0.001), with a median difference of −0.03 kg (interquartile range 
−2.8 to 2.9).
Covariates
Demographic information included age, sex, and race, coded as white, African-American, 
Asian, Hispanic, other, or unknown. We identified heart failure patients through Natural 
Language Processing (NLP) searching of the Past Medical History section of the admission 
examination or Elixhauser discharge coding (24). We also used oral diabetes medication or 
insulin usage, along with Elixhauser discharge coding, to identify diabetic patients. All 
additional Elixhauser discharge coding comorbidities except for “acute renal failure” and 
“obesity” were included as separate variables (24). ICU types included cardiac, surgical, 
cardiothoracic, and medical units. Sequential Organ Failure Assessment (SOFA) scores 
were used to indicate severity of illness. Because of the effect of hemodynamics on renal 
function, we also included systolic and diastolic blood pressure, heart rate, and temperature 
as independent variables. Admission creatinine, defined as the first available creatinine 24 
hours prior to, or six hours after, ICU admission, was used as a determinant of “baseline” 
kidney function. Admission hemoglobin was also included. Because obesity is likely 
associated with increased diuretic, angiotensin-converting-enzyme inhibitor (ACE-I), 
angiotensin-receptor blocker (ARB), and statin usage, we used NLP searches of pre-hospital 
medication lists to identify these exposures. All admission values, except for creatinine, 
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were taken from the first available laboratory data within twenty four hours of ICU 
admission.
Statistical Analysis
We present descriptive baseline characteristics stratified by BMI. We used logistic 
regression to examine the association between BMI, defined categorically and continuously, 
and odds of AKI, based on serum creatinine changes. We adjusted for age, gender, race, 
ICU type, SOFA score, history of diabetes, congestive heart failure, hypertension, chronic 
obstructive pulmonary disease, peripheral vascular disease and 22 additional Elixhauser 
comorbidities, admission systolic and diastolic blood pressure, heart rate, temperature, 
creatinine and hemoglobin, and pre-illness diuretic, ACE-I, ARB, or statin use.
We describe the incidence of AKI stages I to III per BMI classification. We used ordinal 
logistic regression to describe the adjusted risk of a one-step increase of AKI severity with 
an increase of BMI. In separate logistic regressions, we then examined the risk of having 
either Stage II or III AKI compared to either no AKI or Stage I AKI, and the risk Stage III 
AKI, compared to no AKI, Stage I, or Stage II AKI.
To contextualize the clinical significance of an episode of AKI in obesity, we used logistic 
regression to define the adjusted risk of an episode of AKI on within-hospital mortality 
within each BMI category. We also describe the effect of AKI on long term survival 
according to BMI in hospital survivors. We used Cox regression analyses, censoring those 
who survived 365 days or more, and adjusting for the same variables as above, within each 
BMI category.
In sensitivity analyses, to further explore potential mechanisms for the observed strong 
association of increasing BMI with risk of AKI, we performed sequential logistic 
regressions examining how the addition of admission proteinuria, defined as trace or greater 
on urinary dipstick measurement, and admission central venous pressure, obtained within 
the first six hours of admission, changed the association of BMI with AKI. In addition, we 
used creatinine measurements obtained prior to seven days from ICU admission as 
“baseline” in 7000 patients with available measurements.
For all analyses, normal weight was considered the reference category. All analyses were 
performed using JMP Pro (SAS Institute, Cary, NC).
Results
Baseline characteristics
Of 14986 critically ill patients admitted to a medical or surgical intensive care unit with 
available data, 431 (3%) were underweight, 4271 (28%) were normal weight, 5047 (34%) 
were overweight, 2908 (19%) had class I obesity, 1292 (9%) had class II obesity, and 1037 
(7%) had class III obesity. Obesity was associated with a higher prevalence of heart failure, 
hypertension and diabetes than those with normal BMIs, and greater exposure to diuretics, 
ACE-Is, ARBs, and statins prior to admission (Table I). Admission blood pressure tended to 
Danziger et al. Page 4
Crit Care Med. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
be similar across BMI categories. Admission creatinines tended to be higher in obese 
patients.
BMI and incidence and severity of AKI
During the course of critical illness, 3122 (21.1%) individuals developed AKI. As seen in 
Table II, the incidence and adjusted risk of AKI progressively increased with higher BMI. 
Each 5 kg/m2 increment in admission BMI was associated with a 10% [95%CI 1.06–1.24; 
p<0.001] higher adjusted risk of AKI in a model that accounted for demographics, 
comorbidities, severity of critical illness, medication exposure, and admission creatinine. As 
a frame of reference, diabetes was associated with a 1.26 [95% CI 1.15–1.38; p<0.001] 
higher risk of AKI.
The incidence of AKI severity according to BMI is illustrated in Figure 1. In adjusted 
analysis, a 5 kg/m2 increment was associated with a 9% higher risk [95% CI 1.06–1.22; 
p<0.001] of having a higher stage of AKI. As seen in table III, the risk of having Stage II or 
III AKI, compared to either no AKI or stage I AKI, or Stage III AKI, compared to no AKI, 
stage I, or stage II AKI, increased progressively with higher BMI relative to normal weight 
patients.
AKI and survival
There were 1513 (10%) deaths during the critical illness hospitalization. The association of 
AKI with in-hospital mortality was modified by BMI (multiplicative interaction term 
p<0.01). When stratified by BMI category, AKI was consistently associated with a 
significantly higher risk of death (Table IV). When stratified by AKI, a protective effect of 
obesity on hospital survival was observed in those without AKI, as has previously been 
reported. A 5 kg/m2 BMI increase was associated with a 0.89 [95% CI 0.85–0.94; p<0.001] 
odds ratio of within-hospital death in those without AKI. However, in those with AKI, each 
5 kg/m2 BMI increase was associated with a 0.98 [95% CI 0.96–1.09; p=0.59] risk of 
within-hospital death.
Amongst 13,473 hospital survivors, 1568 (12%) died within one year of hospital discharge. 
The association of AKI with subsequent one-year mortality was not modified by BMI 
(multiplicative interaction term= 0.43). Similarly, an episode of AKI during critical illness 
was associated an increased risk of dying within the following one year across BMI 
categories (Table IV).
Sensitivity analyses
Among patients with available data, CVP (n=4017) and prevalence of admission proteinuria 
(n=5753) increased progressively with higher BMI (Figure 2). Addition of CVP into the 
multivariate adjusted model reduced the odds ratio minimally (OR1.08, 95%CI 1.02–1.14; 
p=0.003], per 5 kg/m2 BMI increase), and in 2116 participant with both measurements, each 
5 kg/m2 increment was associated with a 1.08 [95% CI 1.01–1.16; p=0.03] increased risk of 
AKI. Defining baseline renal function by a serum creatinine obtained more than seven days 
prior to critical illness, rather than by the admission creatinine, did not meaningfully change 
the association between BMI and AKI. In 7891 patients with available pre-illness serum 
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creatinine measurements, the correlation between pre-illness and admission serum creatinine 
measurements was 0.68 (p<0.001). Each 5 kg/m2 increment remained associated with a 1.08 
[95% CI 1.01–1.16; p=0.02] increased risk of AKI.
Discussion
Our findings highlight obesity as a risk factor for AKI during critical illness. In models that 
adjusted for comorbidities, acuity of illness, pre-illness ACE, ARB, and diuretic use, each 5 
kg/m2 was associated with a ten percent increased risk of AKI. Furthermore, these episodes 
of AKI were associated with worse short and long term survival.
Our findings supplement a growing awareness of the susceptibility to AKI in obesity. In a 
recent study of almost 500 critically ill patients with acute respiratory distress, each 5 kg/m2 
increase in BMI was associated with a 20% increased risk of AKI (15). In a large Austrian 
study, severely obese patients had a greater than 2 fold increased risk of severe AKI than 
normal weighted patients (16). Long term survival was not available in either study. More 
recent studies, however, have not identified obesity as a significant risk factor for AKI (7).
Our observed association between obesity and AKI raise questions about potential 
pathophysiologic mechanisms (25). The hemodynamic perturbations associated with obesity 
could explain an increased susceptibility (26). Cor pulmonale, a result of hypoventilation, 
sleep apnea, and pulmonary hypertension, occurs frequently in obesity (27, 28), and leads to 
sodium avidity and peripheral venous congestion. Obese patients have higher right sided 
filling pressures (29) and greater diuretic requirements (30) than those with normal weight. 
The role of venous congestion as a determinant of renal function has been known for over 
80 years, with early physiology experiments highlighting that increased renal venous 
pressures decreased urine formation (31, 32). More recent clinical data has focused on 
peripheral venous congestion in heart failure (33), where CVPs, but not cardiac output or 
pulmonary capillary wedge pressures, are associated with renal dysfunction, highlighting the 
importance of the trans-renal pressure gradient, a balance between renal arterial perfusion 
and venous drainage, as a determinant of renal function. Similarly, increasing CVP has been 
associated with AKI in sepsis (34).
In our analysis, increasing BMI was associated with higher CVPs obtained within six hours 
to the ICU. However, inclusion of CVP measures did not significantly attenuate nor modify 
the association between BMI and AKI, suggesting additional factors may exist.
Recent data has highlighted organ-specific abnormalities in obesity, with changes seen both 
within the kidney and the heart. Obesity leads to renal glomerular hypertrophy and 
hyperfiltration (35) which potentially contribute to renal susceptibility. More recently, an 
“adipose-renal” hormonal axis has emerged. Adiponectin, an insulin sensitizing hormone 
that regulates glucose and lipid metabolism, and which is markedly decreased in visceral 
obesity, is protective in some models of renal ischemia reperfusion injury, although 
considered pathogenic in others (36). Leptin, an adipocyte derived cytokine that is 
metabolized in the kidney and controls energy metabolism and appetite, modulates 
susceptibility to endotoxin-mediated renal failure and stimulates proliferation and fibrosis 
Danziger et al. Page 6
Crit Care Med. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(37, 38). Autophagy, an important internal degradation system whereby cells can removed 
damaged proteins and organelles, is impaired in obesity (1). Cardiac changes associated with 
obesity also might affect renal perfusion. In addition to increased left ventricular 
hypertrophy, direct infiltration of the myocardium has been reported, termed 
“cardiomyopathy of obesity” (39–41). Thus, whether kidney or cardiac specific changes 
associated with obesity contribute to the incidence of AKI is plausible.
In addition to establishing obesity as a risk for AKI, our data highlights the associated short- 
and long-term outcomes associated with AKI. In our analysis, even though obese patients 
were more likely to develop AKI, these AKI episodes were not less significant. Rather, 
across BMI categories, AKI was associated with increased within-hospital mortality and 
one-year mortality. In addition, whereas obesity has paradoxically been associated with an 
improved prognosis in critical illness, this protective association is absent in patients with 
AKI. Whether renal protective strategies, including minimizing radiographic contrast and 
potentially nephrotoxic medications, careful use of diuretics, and careful blood pressure 
management to minimize hypotension, might improve outcomes, remains speculative.
Limitations
Although our study had a number of strengths, including an extremely large dataset with 
ample power and systematic assessment of mortality, the observational nature of our 
analysis limits any conclusions of causality. Furthermore, although the large number of 
patients and the multiple covariates allow for adjustment, it is plausible that confounding 
remains. Given the unaccounted effect of critical illness on weight, and the lack of 
information about weight changes prior to admission, confounding due to malnutrition, 
cachexia, and fluid retention likely remains, although we would not expect non-adipose 
contributors to BMI such as fluid retention to be associated with improved one-year 
mortality. In addition, our manual review of randomly selected charts suggests a strong 
correlation between critical and non-critical illness BMI values. In addition, we used 
admission serum creatinines to account for baseline function, which likely leads to 
misclassification. However, in a subset of patients with available creatinine measurements 
prior to critical illness, admission and baseline creatinines were highly correlated, and the 
association of BMI with AKI remained robust. Furthermore, because the baseline serum 
creatinine may be increased in obesity, our outcome of a relative change in creatinine should 
be conservative and hence this would bias our findings towards the null.
Conclusions
Obese patients are more likely to develop AKI, which is associated with increased short and 
long term mortality. Whether renal protective strategies during critical illness might improve 
outcomes will require further investigation.
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Figure 1. 
Percentage of patients stratified by BMI who develop Stage I, II, and III AKI within seven 
days of ICU admission.
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Figure 2. 
Mean admission central venous pressure and percentage of patients with admission 
proteinuria stratified by BMI.
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